Akesis, Profil to launch clinical trials in type 2 diabetes

By Elaine Rigoli

Tampa, Fla., May 4 - Akesis Pharmaceuticals, Inc. has entered into a consulting agreement with Profil Institute for Clinical Research, Inc. under which the parties will develop a clinical research protocol and conduct other activities to support the start of new clinical trials in type 2 diabetes.

Akesis is developing a set of proprietary product formulations designed to lower and control blood glucose levels in patients with type 2 diabetes.

The company has conducted an open-label initial clinical trial using one of these formulations, which demonstrated an average two-point decline in glycated hemoglobin levels, compared to base line, after three months of treatment in a diabetic population, according to a news release.

A double-blind, placebo controlled clinical trial in type 2 diabetic patients under development by Akesis and Profil is being designed with a goal of confirming and extending the results of the initial study, the release said.

Based in Chula Vista, Calif., Profil develops new therapeutics and devices to serve the diabetic community.

Akesis is a pharmaceutical company based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.